BIOGEN INC. (BIIB) Stock Profile — Insider Trades & Financials

Revenue$2.3B

Net Income-$48.9M

EPS$8.79

Market Cap$25.8B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Christopher A. Viehbacher

CEO & Executive Director

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia ; tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.

Employees: 7,605
Headquarters: CAMBRIDGE, MA, United States
Website

⚡

Core Efficiency

ROE?

-0.27%

ROA?

-0.17%

D/E Ratio?

0.61

📊

Profitability Ratios

Net Margin?

-2.15%

Current Ratio?

2.68

Loading company sections...

BIOGEN INC.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness